Xiamen Historical Income Statement
| 688278 Stock | 73.51 0.41 0.56% |
Historical analysis of Xiamen Amoytop income statement accounts such as Net Interest Income of 7.1 M, Interest Expense of 432.8 K or Selling General Administrative of 531.3 M can show how well Xiamen Amoytop Biotech performed in making a profits. Evaluating Xiamen Amoytop income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Xiamen Amoytop's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Xiamen Amoytop Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Xiamen Amoytop Biotech is a good buy for the upcoming year.
Xiamen |
About Xiamen Income Statement Analysis
Xiamen Amoytop Biotech Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Xiamen Amoytop shareholders. The income statement also shows Xiamen investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Xiamen Amoytop Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Xiamen Amoytop Biotech generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Xiamen Amoytop Biotech minus its cost of goods sold. It is profit before Xiamen Amoytop operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Xiamen Amoytop Biotech. It is also known as Xiamen Amoytop overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Xiamen Amoytop's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Xiamen Amoytop Biotech current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Xiamen Amoytop Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At present, Xiamen Amoytop's Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Net Interest Income is expected to grow to about 7.1 M, whereas Interest Expense is forecasted to decline to about 432.8 K.
| 2022 | 2023 | 2024 | 2025 (projected) | Gross Profit | 1.4B | 2.0B | 2.3B | 2.4B | Total Revenue | 1.5B | 2.1B | 2.4B | 2.5B |
Xiamen Amoytop income statement Correlations
Click cells to compare fundamentals
Xiamen Amoytop Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Not Found
Xiamen Amoytop income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Tax Provision | 22.5M | 34.1M | 68.9M | 85.2M | 98.0M | 102.9M | |
| Net Interest Income | 96.3K | 1.6M | 3.7M | 5.8M | 6.7M | 7.1M | |
| Interest Expense | 2.5M | 1.1M | 620.7K | 506.2K | 455.6K | 432.8K | |
| Selling General Administrative | 446.8M | 620.4M | 736.5M | 890.3M | 1.0B | 531.3M | |
| Total Revenue | 793.9M | 1.1B | 1.5B | 2.1B | 2.4B | 2.5B | |
| Gross Profit | 710.3M | 1.0B | 1.4B | 2.0B | 2.3B | 2.4B | |
| Other Operating Expenses | 3.7M | 3.8M | 5.5M | 1.1B | 1.3B | 1.4B | |
| Operating Income | 153.6M | 239.7M | 398.1M | 684.4M | 787.1M | 826.4M | |
| Net Income From Continuing Ops | 116.6M | 181.2M | 287.0M | 555.4M | 638.8M | 670.7M | |
| Ebit | 108.9M | 126.9M | 221.6M | 407.2M | 468.2M | 491.7M | |
| Research Development | 76.7M | 81.5M | 149.8M | 230.0M | 264.5M | 277.7M | |
| Cost Of Revenue | 83.6M | 125.1M | 169.2M | 140.1M | 161.1M | 99.9M | |
| Total Operating Expenses | 640.3M | 892.5M | 1.1B | 1.4B | 1.6B | 1.7B | |
| Income Before Tax | 139.1M | 215.3M | 355.9M | 640.7M | 736.8M | 773.6M | |
| Net Income Applicable To Common Shares | 64.3M | 116.6M | 181.2M | 287.2M | 330.3M | 346.8M | |
| Net Income | 116.6M | 181.2M | 287.0M | 555.4M | 638.8M | 670.7M | |
| Income Tax Expense | 26.7M | 22.5M | 34.1M | 68.9M | 79.3M | 83.2M | |
| Interest Income | 2.8M | 2.9M | 4.6M | 6.6M | 7.6M | 8.0M | |
| Ebitda | 135.1M | 179.7M | 259.5M | 404.6M | 465.3M | 488.6M | |
| Reconciled Depreciation | 38.2M | 43.2M | 48.1M | 58.7M | 67.5M | 45.4M |
Currently Active Assets on Macroaxis
Other Information on Investing in Xiamen Stock
Xiamen Amoytop Biotech Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Xiamen Amoytop shareholders. The income statement also shows Xiamen investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).